AOD-9604 bodybuilding: assess fat-loss and muscle claims, unsupported cutting protocols, oral trial history, formulation limits, and WADA prohibition.
AOD-9604 bodybuilding claims focus on fat loss, but a proposed metabolic mechanism does not establish clinical fat loss, muscle preservation, or safety. AOD-9604 has no FDA-approved human drug product, and the 2026 WADA list prohibits it at all times. Community cutting protocols are not validated by its design.
What AOD-9604 Actually Is
AOD-9604 is a modified version of the C-terminal portion of human growth hormone, covering amino acids 177 through 191, with an added tyrosine molecule. Researchers developed it in the 1990s while searching for a compound that could reduce body fat without triggering growth hormone's effects on blood sugar or tissue growth.
The larger oral obesity trial summarized in FDA's 2024 AOD-9604 evaluation enrolled 536 people and randomized 502 to placebo or 0.25, 0.5, or 1 mg daily for 24 weeks. It did not show a significant advantage on the primary weight-loss endpoint at 12 weeks. Oral trial arms are not human injection recommendations.
For aod 9604 peptide bodybuilding, an intended difference from growth hormone cannot guarantee the absence of IGF-1, glucose, or tissue-growth effects across human doses and routes. Nor does it establish a fat-loss or muscle-retention outcome.
Why Bodybuilders Use AOD-9604
Cutting-phase accounts may combine AOD-9604 with dieting, fasted cardio, or other compounds. Those concurrent interventions make attribution harder; low-insulin theories do not establish enhanced clinical fat loss from AOD-9604.
- Targeted fat loss: laboratory lipolysis does not establish a targeted human outcome.
- Hormone safety: a design intended to differ from full HGH does not guarantee fewer adverse effects.
- Stacking: lack of a known interaction is not proof of compatibility.
- Half-life: human pharmacokinetics were not identified for any route in the 2024 review; split dosing cannot be justified from an assumed short half-life.
The reviewed clinical record does not establish muscle mass, strength, recovery, or muscle-preservation benefits. That is an evidence limitation rather than proof of every possible biological effect.
AOD-9604 Dosage: What People Report
No validated human subcutaneous aod 9604 dosage or bodybuilding regimen follows from the reviewed evidence. A repeated daily amount in a log is not a clinical starting dose.
| Protocol variable | Common claim | Evidence boundary |
|---|---|---|
| Daily amount | A common range is a standard | No validated human injection amount established |
| Timing | Fasting or pre-cardio improves results | No validated clinical advantage established |
| Frequency | Split dosing follows a short human half-life | Human pharmacokinetics not identified in the 2024 review |
| Cycle | Eight-to-twelve weeks is appropriate | No validated human injection course established |
| Weekly breaks | Five days on, two off improves safety or response | No validated comparative regimen established |
A community protocol cannot become validated by being described as research. Subjective tolerance, gradual escalation, and medical supervision do not supply missing route-specific dose-finding evidence.
AOD-9604 Benefits and Side Effects
For aod 9604 benefits and side effects, distinguish the substantial oral clinical record from the absence of a validated human subcutaneous profile in the 2024 review.
Reported benefits
- A weight or waist change during a calorie deficit does not establish a peptide effect.
- Absence of a symptom in selected posts does not establish that it is uncommon.
- A claim of painless injections does not establish product identity, sterility, or suitability.
Reported side effects
- Forum redness, swelling, headache, nausea, or fatigue reports are not a measured incidence or proof of causality.
- The reviewed human safety information concerned oral and intravenous administration.
- Some serious oral events were reported without enough information to establish causality; this does not prove the drug caused them or that injections are safe.
Animal research has raised questions about how AOD-9604 affects immune and inflammatory markers. The clinical significance of those findings in humans is not known.
AOD-9604 vs Tesamorelin and MOTS-c
These three peptides are often grouped together as fat-loss compounds, but they work in very different ways.
| Compound | Relevant identity | Clinical interpretation |
|---|---|---|
| AOD-9604 | Modified growth-hormone fragment | No FDA-approved human product or validated human injection regimen in the reviewed evidence |
| Tesamorelin | GHRH analog | Approved products have a specific HIV-related indication and product-specific monitoring |
| MOTS-c | Mitochondrial-derived peptide | A metabolic mechanism does not establish clinical fat loss or stack safety |
Tesamorelin evidence applies to its actual indication and product. MOTS-c mechanisms and AOD-9604 laboratory findings cannot establish an evidence ranking for bodybuilding, equivalent effects, or a suitable combination.
Reconstitution and Storage
Aod 9604 reconstitution requires compatibility and stability evidence for the actual form and formulation. Bacteriostatic water is not automatically a valid solvent for every sample.
- Identify the batch, form, and intended assay.
- Use documented solvent and preparation compatibility rather than a generic injection recipe.
- Use final solution volume for concentration arithmetic, assuming complete dissolution.
- Use storage conditions supported for that preparation; a freezer or refrigerator rule is not universal.
As hypothetical laboratory arithmetic, 2 mg in a final volume of 2 mL gives 1 mg/mL. A specified 300 mcg aliquot occupies 0.3 mL; this is not a human dose or preparation recipe. The 2024 evaluation explains that formulation, pH, concentration, temperature, impurities, and excipients can affect aggregation and degradation. It does not validate one diluent, acid recipe, or shelf life for every AOD-9604 product. A generic four-week shelf life is not established.
Stacking AOD-9604 With Tirzepatide
For aod 9604 with tirzepatide, the 2024 evaluation does not establish combination efficacy, muscle preservation, safety, or an appropriate dose. Approval of a tirzepatide product does not validate a stack.
Concurrent compounds can complicate attribution of symptoms and changes. Specific interaction effects or amplified nausea and fatigue require evidence rather than assumption; clinical discussion does not make an unsupported stack proven.
Legal Status and Drug Testing
AOD-9604 is not FDA-approved for human use in the United States. It is sold as a research chemical that is not for human consumption, which means the quality, purity, and actual content of vials are not guaranteed.
The 2026 WADA Prohibited List explicitly names AOD-9604 under S2.2.3 among growth-hormone fragments, prohibited at all times. Sanctions depend on applicable anti-doping rules and case circumstances; this listing alone does not establish a detection window or an automatic multi-year sanction.
The Bottom Line for Bodybuilders
A plausible mechanism does not establish bodybuilding fat loss, muscle benefits, or safety. AOD-9604 has no FDA-approved human product and is prohibited under the applicable WADA list. Changes during dieting or cardio cannot be attributed to the peptide without appropriate controls.
Better-evidenced options exist for fat loss, including calorie control, resistance training, and FDA-approved medications prescribed by a physician. If you are considering AOD-9604 anyway, talk to a healthcare provider first and be realistic about the risks.
Frequently Asked Questions
Does AOD-9604 build muscle?
Muscle growth, strength, recovery, and muscle-preservation benefits are not established by the reviewed human clinical record. The design intended to differ from full growth hormone does not prove a universal absence of hormone effects or establish a bodybuilding benefit.
What is the typical AOD-9604 dosage for bodybuilding?
No validated human subcutaneous bodybuilding dose is established by the reviewed evidence. Community amounts, split schedules, cycles, and five-on/two-off routines are not clinical dose-finding.
Is AOD-9604 legal in the United States?
No FDA-approved AOD-9604 human drug product exists. A research label does not authorize treatment or settle every legal circumstance. The 2026 WADA list names AOD-9604 under S2.2.3, prohibited at all times; sanctions depend on applicable rules and case details.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.